Table 3 Outcome after therapeutic splenectomy
From: Efficacy of prophylactic splenectomy for proximal advanced gastric cancer invading greater curvature
Recurrence (n = 17) | No recurrence (n = 9) | p value | |
|---|---|---|---|
Clinical findings | |||
Age, median (range) | 59.0 (38–78) | 60.0 (43–66) | 0.358 |
Sex | 0.484 | ||
Male | 7 | 5 | |
Female | 10 | 4 | |
Borrmann macroscopic type | 0.463 | ||
Type 2 | 1 | 2 | |
Type 3 | 7 | 3 | |
Type 4 or 5 | 9 | 4 | |
Histopathological type | 0.778 | ||
Intestinal | 3 | 2 | |
Diffuse | 14 | 7 | |
Operative findings | |||
Operative procedure | 0.143 | ||
Splenectomy | 3 | 4 | |
Splenectomy + pancreatectomy | 14 | 5 | |
Curability | 0.161 | ||
CurA | 0 | 1 | |
CurB | 17 | 8 | |
Final stage | 0.359 | ||
Stage IIIA | 2 | 2 | |
Stage IIIB | 12 | 7 | |
Stage IIIC | 3 | 0 | |
Lymph node metastasis at the splenic hilum | 17 | 9 | |
Lymph node metastasis along the splenic artery | 5 | 4 | |
Median survival period (months) | 22.9 | 140.9 | <0.001 |
Main recurrent patterns | |||
Peritoneal dissemination | 16 (94.1%) | ||
Lymph node metastasis | 1 (5.9%) | ||